MicroRNA in urine as potential biomarker for bladder cancer detection and follow-up

162 MicroRNA in urine as potential biomarker for bladder cancer detection and follow-up Brisuda A.1, Pospisilova S.2, Soukup V.3, Hrbacek J.1, Capoun O.3, Mares J.4, Pazourkova E.2, Korabecna M.2, Horinek A.2, Hanus T.3, Babjuk M.1 1 2nd Faculty of Medicine, Charles University and University Hospital Motol, Dept. of Urology, Prague, Czech Republic, 2Department of Biology and Human Genetics, 1st Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic, 31st Faculty of Medicine, Charles University and General Faculty Hospital, Dept. of Urology, Prague, Czech Republic, 4Charles University In Prague, 2nd Faculty of Medicine, Department of Biology and Medical Genetics, Prague, Czech Republic INTRODUCTION & OBJECTIVES: MicroRNAs (miRNAs) are short non-coding RNA molecules that influence expression of genes and thus participate on many physiological and pathological processes. The aim of the study was to identify a panel of miRNAs which are detectable in urine and can be used for diagnosis of bladder cancer and possibly establishing the prognosis of the patients. MATERIAL & METHODS: In total, 61 individuals were included into the study (15 controls and 46 patients with bladder cancer of different stages). Their sterile urine was collected in a standardized way (patients with urine infection were not included). In the first part of the study 381 miRNAs were analysed in every urine sample using TaqMan MicroRNA Array. Obtained results were afterwards specified using TaqMan MicroRNA Assays for every single miRNA. Both techniques used real-time PCR. Three miRNAs (miR-191, miR-28-3p and miR-200b), chosen by the geNorm analysis within the qBase+© programme, were used for the normalization of the expression rate. Man-Whitney´s U test with Benjamini-Hochberg correction was used for statistical analysis of the acquired data. RESULTS: In the first part of the study 58 miRNAs were identified whose expression was significantly different between controls and patiens (p < 0.05). Ten of these miRNAs were verified by TaqMan MicroRNA Assays (let-7c, miR-125b, miR-204, miR-425, miR-532-3p, miR-99a, miR-16, miR-30b, miR-93 and miR-199a-3p). Six miRNAs were 4-10 times more expressed in controls. Four miRNAs were 2-4 times more expressed in patients. CONCLUSIONS: We found 10 miRNAs with highly significant differences in their expressions in urine of patients and controls. These miRNAs will be used in subsequent validation study. These miRNAs will be tested whether they can predict tumour stage and grade and whether they can predict tumour`s recurrence after complete resection by TURB during follow-up. Acknowledgements: Supported by the Internal Grant Agency of the Ministry of Health of the Czech Republic No. NT12417. Eur Urol Suppl 2015; 14(6): e1318